Lumida
/ALLO
⌘K
Allogene Therapeutics Inc

Allogene Therapeutics Inc

ALLO
$1.78USD+1.14%+0.02 today

MARKET CAP

615.0M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$4

AI Summary

Stalk
TrimMedium

Following a Stage 1 consolidation attempt after a terminal decline, the stock exhibits a repaired EMA regime yet remains under an active Lower Highs & Lower Lows pattern, reinforcing a medium-term bearish bias. In the short term, price is tightly tracking above the rising 9/21-EMA zone without a clear rejection signal, arguing for patience and deferred execution until a more decisive breakdown or EMA rejection occurs.

  • Phase 2 ALPHA3 trial cema-cel shows 58.3% MRD negativity vs 16.7% control.
  • FDA granted RMAT and Fast Track designations, expediting approval path.
  • Negative earnings yield and profitability scores signal weak returns.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2021FY 2022FY 2023FY 2024TREND
Sales, Adj.$0$114.1M$156,000$95,000$22,000
YoY %-99.9%-39.1%-76.8%
P / Sales17.8x5285.4x5979.9x18861.3x
EV / Sales17.3x5880.3x6479.4x21193.7x
Gross Profit, Adj.$0$114.1M$156,000$95,000$22,000
YoY %-99.9%-39.1%-76.8%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit17.3x5880.3x6479.4x21193.7x
EBITDA, Adj.$-197.2M$-169.7M$-321.2M$-300.3M$-243.8M
YoY %-3.1%+32.3%-89.3%+6.5%+18.8%
Margin %-148.8%-205923.7%-316097.9%-1108377.3%
EV / EBITDA-12.9x-11.7x-2.9x-2.0x-1.9x
EBIT$-202.3M$-180.2M$-335.5M$-327.7M$-273.2M
YoY %-4.9%+30.2%-86.2%+2.3%+16.6%
Margin %-157.9%-215087.2%-344986.3%-1241813.6%
EV / EBIT-12.6x-11.0x-2.7x-1.9x-1.7x
Net Income$-184.6M$-182.1M$-340.4M$-327.3M$-257.6M
YoY %+12.7%+42.5%-87.0%+3.9%+21.3%
Net Margin-159.6%-218214.1%-344489.5%-1170863.6%
EPS (GAAP)-$1.83-$1.34-$2.38-$2.09-$1.32
YoY %+75.0%+49.0%-77.6%+12.2%+36.8%